Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
From MaRDI portal
(Redirected from Publication:6577811)
Cites work
- A Bayesian dose-finding design for drug combination trials with delayed toxicities
- A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data
- A Curve‐Free Method for Phase I Clinical Trials
- A simple technique to evaluate model sensitivity in the continual reassessment method
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Bayesian optimal interval designs for phase I clinical trials
- Bayesian uncertainty-directed dose finding designs
- Coherence principles in dose-finding studies
- Consistency of continual reassessment method under model misspecification
- Continual Reassessment Method: A Likelihood Approach
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Cumulative cohort design for dose-finding
- Design and Analysis of Phase I Clinical Trials
- Dose-finding designs: the role of convergence properties
- scientific article; zbMATH DE number 3567782 (Why is no real title available?)
- Robust EM continual reassessment method in oncology dose finding
- Semiparametric Dose Finding Methods
- Semiparametric dose finding methods: special cases
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- The Calculation of Posterior Distributions by Data Augmentation
- TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
This page was built for publication: Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6577811)
